Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer

Report from the adelaide colorectal tumour group meeting; Stockholm, Sweden; September 2008

Timothy J. Price, Niall C. Tebbutt, Christos S. Karapetis, Eva Segelov, Nick Pavlakis, David Cunningham, Alberto F. Sobrero, Daniel G. Haller, Jeremy D. Shapiro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the optimal timing of their use requires careful consideration in order to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and epidermal growth factor receptor-targeted biologic agents (cetuximab and panitumumab) in the treatment of patients with mCRC. This article reviews the evidence in support of modern treatments for mCRC and the decision making behind the treatment choices as well as their benefits and toxicities. An evidence-based algorithm is proposed that incorporates the use of these biologic agents early in the treatment of patients with initially nonresectable mCRC based on clearly defined tumor-related factors dependent on the immediate treatment goal. Real-world application of this algorithm is dependent on an individual countries' approval of access to new biologic agents.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalClinical Colorectal Cancer
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Group Processes
Sweden
Colorectal Neoplasms
Biological Factors
Therapeutics
Epidermal Growth Factor Receptor
Decision Making
Monoclonal Antibodies
Drug Therapy

Keywords

  • 5-Fluorouracil
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • KRAS
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer : Report from the adelaide colorectal tumour group meeting; Stockholm, Sweden; September 2008. / Price, Timothy J.; Tebbutt, Niall C.; Karapetis, Christos S.; Segelov, Eva; Pavlakis, Nick; Cunningham, David; Sobrero, Alberto F.; Haller, Daniel G.; Shapiro, Jeremy D.

In: Clinical Colorectal Cancer, Vol. 9, No. 1, 01.01.2010, p. 8-14.

Research output: Contribution to journalArticle

Price, Timothy J. ; Tebbutt, Niall C. ; Karapetis, Christos S. ; Segelov, Eva ; Pavlakis, Nick ; Cunningham, David ; Sobrero, Alberto F. ; Haller, Daniel G. ; Shapiro, Jeremy D. / Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer : Report from the adelaide colorectal tumour group meeting; Stockholm, Sweden; September 2008. In: Clinical Colorectal Cancer. 2010 ; Vol. 9, No. 1. pp. 8-14.
@article{8422a765f77e4a6c9a78ce1db639fe18,
title = "Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: Report from the adelaide colorectal tumour group meeting; Stockholm, Sweden; September 2008",
abstract = "The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the optimal timing of their use requires careful consideration in order to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and epidermal growth factor receptor-targeted biologic agents (cetuximab and panitumumab) in the treatment of patients with mCRC. This article reviews the evidence in support of modern treatments for mCRC and the decision making behind the treatment choices as well as their benefits and toxicities. An evidence-based algorithm is proposed that incorporates the use of these biologic agents early in the treatment of patients with initially nonresectable mCRC based on clearly defined tumor-related factors dependent on the immediate treatment goal. Real-world application of this algorithm is dependent on an individual countries' approval of access to new biologic agents.",
keywords = "5-Fluorouracil, Bevacizumab, Capecitabine, Cetuximab, KRAS, Vascular endothelial growth factor",
author = "Price, {Timothy J.} and Tebbutt, {Niall C.} and Karapetis, {Christos S.} and Eva Segelov and Nick Pavlakis and David Cunningham and Sobrero, {Alberto F.} and Haller, {Daniel G.} and Shapiro, {Jeremy D.}",
year = "2010",
month = "1",
day = "1",
doi = "10.3816/CCC.2010.n.001",
language = "English",
volume = "9",
pages = "8--14",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer

T2 - Report from the adelaide colorectal tumour group meeting; Stockholm, Sweden; September 2008

AU - Price, Timothy J.

AU - Tebbutt, Niall C.

AU - Karapetis, Christos S.

AU - Segelov, Eva

AU - Pavlakis, Nick

AU - Cunningham, David

AU - Sobrero, Alberto F.

AU - Haller, Daniel G.

AU - Shapiro, Jeremy D.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the optimal timing of their use requires careful consideration in order to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and epidermal growth factor receptor-targeted biologic agents (cetuximab and panitumumab) in the treatment of patients with mCRC. This article reviews the evidence in support of modern treatments for mCRC and the decision making behind the treatment choices as well as their benefits and toxicities. An evidence-based algorithm is proposed that incorporates the use of these biologic agents early in the treatment of patients with initially nonresectable mCRC based on clearly defined tumor-related factors dependent on the immediate treatment goal. Real-world application of this algorithm is dependent on an individual countries' approval of access to new biologic agents.

AB - The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the optimal timing of their use requires careful consideration in order to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and epidermal growth factor receptor-targeted biologic agents (cetuximab and panitumumab) in the treatment of patients with mCRC. This article reviews the evidence in support of modern treatments for mCRC and the decision making behind the treatment choices as well as their benefits and toxicities. An evidence-based algorithm is proposed that incorporates the use of these biologic agents early in the treatment of patients with initially nonresectable mCRC based on clearly defined tumor-related factors dependent on the immediate treatment goal. Real-world application of this algorithm is dependent on an individual countries' approval of access to new biologic agents.

KW - 5-Fluorouracil

KW - Bevacizumab

KW - Capecitabine

KW - Cetuximab

KW - KRAS

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=77149128980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149128980&partnerID=8YFLogxK

U2 - 10.3816/CCC.2010.n.001

DO - 10.3816/CCC.2010.n.001

M3 - Article

VL - 9

SP - 8

EP - 14

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 1

ER -